Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PERFUSE - One-year Persistence to Treatment of Patients Receiving Flixabi or Imraldi: a French Cohort Study

NCT03662919 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT03662919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03662919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PERFUSE - One-year Persistence to Treatment of Patients Receiving Flixabi or Imraldi: a French Cohort Study
Lead sponsor
Biogen
Phase
Observational
Overall status
Completed
Start date
July 2, 2018
Completion date
June 30, 2022
Enrollment
2,274 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, psoriatic, arthritis, rheumatoid, colitis, ulcerative, crohn's disease, spondylitis, ankylosing